Gout drug reduces adverse events in patients with hyperuricaemia

August 28, 2018

Munich, Germany - 28 Aug 2018: Uric acid reduction with the gout treatment febuxostat reduces adverse events in elderly patients with hyperuricaemia, according to late breaking research presented today in a Hot Line Session at ESC Congress 2018.1

Hyperuricaemia, an abnormally high serum uric acid level, causes gout and is associated with coronary artery disease, hypertension, stroke, renal failure, and death. The FREED study2 examined whether lowering uric acid with febuxostat prevents cerebral, cardiovascular and renal events and death in elderly patients with the condition.

The study enrolled 1,070 patients aged 65 years and older with hyperuricaemia (serum uric acid 7-9 mg/dL) and at risk for cerebral, cardiovascular, or renal events as defined by the presence of hypertension, type 2 diabetes, renal disorder, or a history of cerebral or cardiovascular disease.3

Patients were randomly assigned in a 1:1 ratio to receive oral febuxostat for 36 months or not. In the febuxostat group, the dose was increased stepwise from 10 to 40 mg per day if tolerated. In the non-febuxostat group, allopurinol 100 mg was considered if serum uric acid was elevated. In both groups, the dose of febuxostat or allopurinol was adjusted to avoid a serum uric acid level less than 2 mg/dL. All patients were advised to consume a healthy diet, quit smoking, and exercise to help manage their hyperuricaemia.

Patients were followed-up for 36 months for the primary endpoint which was a composite of cerebral, cardiovascular, and renal events, and death from any cause. This consisted of death due to cerebral or cardiorenal vascular disease, new or recurring cerebrovascular disease, new or recurring coronary artery disease, cardiac failure requiring hospitalisation, arteriosclerotic disease requiring treatment, renal disease (development of microalbuminuria, progression to overt proteinuria, or worsening of overt proteinuria to ?300 mg/g albumin/creatinine, doubling of serum creatinine level, progression to end stage renal disease defined as estimated glomerular filtration rate <15 ml>

A total of 537 patients received febuxostat and the average dose at the end of the study was 29 mg. Of the 533 patients in the non-febuxostat group, 27% received allopurinol 100 mg. Average serum uric acid levels reached 4.4 mg/dL in the febuxostat group and 6.7 mg/dL in the group not receiving febuxostat.

The primary endpoint occurred in 125 (23%) patients in the febuxostat group and 153 (29%) patients in the non-febuxostat group. Febuxostat significantly reduced the rate of the primary endpoint, with a hazard ratio of 0.75 (95% confidence interval 0.59-0.95, p=0.017) (see figure).

When the individual components of the primary endpoint were analysed separately, the most frequent event was renal impairment, which occurred in 16.2% of the febuxostat group and 20.5% of the non-febuxostat group. Among those with renal impairment, the development of microalbuminuria or mild proteinuria was common in both treatment groups.

Adverse events were observed in 132 (24.6%) patients in the febuxostat group and 135 (25.3%) patients in the non-febuxostat group, with no significant difference between the two groups (p=0.83). Two patients in the febuxostat group died. Also in the febuxostat group, mental disorder, headache, hypertension, abdominal pain, diarrhoea, maculopapular rash, acute kidney injury, and oedema of the extremities occurred in two patients each.

Professor Sunao Kojima, principal investigator, Kawasaki Medical School, Okayama, Japan, said: : "We found that patients receiving febuxostat were 25% less likely to die or experience strokes, heart disease, or kidney disease over a three-year period than patients who did not receive febuxostat. The findings suggest that lowering uric acid with febuxostat provides clinical benefit."
-end-
Figure: Kaplan-Meier curves for the primary composite event

Notes to editors

SOURCES OF FUNDING: Teijin Pharma Limited.

DISCLOSURES: None.

References

1 "FREED - Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy" will be discussed during:2 FREED: Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.

3 Kojima S, Matsui K, Ogawa H, et al. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017;69:169-175. doi: 10.1016/j.jjcc.2016.02.015.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2018

ESC Congress is the world's largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.

More information is available from the ESC Press Office at press@escardio.org.

European Society of Cardiology

Related Coronary Artery Disease Articles from Brightsurf:

Researchers use multi-ancestry comparison to refine risk factors for coronary artery disease
An international group led by researchers from the RIKEN Center for Integrative Medical Sciences have used a combination of genome-wide association analysis--or GWAS--and a trans-ancestry comparison of different GWAS studies, to come up with a more accurate predictor of coronary artery disease based on genetic factors.

Oral radiography can reveal chronic coronary artery disease
A study found a link between carotid artery calcification observable in radiographs and coronary artery disease as well as several oral infections.

A new strategy to counter insulin damage in coronary artery disease
By studying blood vessel tissue from 674 patients, a research team has discovered how insulin contributes to the dysfunction of blood vessels in atherosclerosis, one of the most common chronic health conditions worldwide.

3D fusion imaging improves coronary artery disease diagnosis
A new technique that combines CT and MRI can bolster coronary artery disease diagnosis and help to define appropriate treatment for patients suffering from the disease, according to a new study.

Associations between vaspin levels and coronary artery disease
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0565, Lutfu Askin, Okan Tanriverdi, Hakan Tibilli and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider associations between vaspin levels and coronary artery disease.

Waist size, not body mass index, may be more predictive of coronary artery disease
For years, women have been told that weight gain could lead to heart disease.

Women with coronary artery wall thickness at risk for heart disease
The thickness of the coronary artery wall as measured by MRI is an independent marker for heart disease in women, according to a new study.

SPIE journal reports advances in use of 3D models in assessing coronary artery disease
In an article published in SPIE's Journal of Medical Imaging (JMI), researchers announce critical advances in the use of 3D-printed coronary phantoms with diagnostic software, further developing a non-invasive diagnostic method for Coronary Artery Disease (CAD) risk assessment.

E-cigarettes linked to heart attacks, coronary artery disease and depression
Concerns about the addictive nature of e-cigarettes -- now used by an estimated 1 out of 20 Americans -- may only be part of the evolving public health story surrounding their use, according to data being presented at the American College of Cardiology's 68th Annual Scientific Session.

Is guideline-recommended therapy for coronary artery disease more likely in Medicare Advantage?
Medicare Advantage is Medicare's managed-care alternative to traditional fee-for-service Medicare.

Read More: Coronary Artery Disease News and Coronary Artery Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.